The 2020 revision of the guidelines for the management of myeloproliferative neoplasms

키워드

참고문헌 (129)

1. "WHO classification of tumours of haematopoietic and lymphoid tissues" (2017)[URL]
2. James C, "A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera", Nature, 434, pp.1144~1148 (2005)
3. Baxter EJ, "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders", Lancet, 365, pp.1054~1061 (2005)
4. 임유주, "Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea", Journal of Korean Medical Science, 31(10), pp.1579~1585 (2016), 대한의학회
5. Byun JM, "Real world epidemiology of myeloproliferative neoplasms : a population based study in Korea 2004-2013", Ann Hematol, 96, pp.373~381 (2017)
6. 최철원, "Guidelines for the management of myeloproliferative neoplasms", The Korean Journal of Internal Medicine, 30(6), pp.771~788 (2015), 대한내과학회[DOI]
7. Arber DA, "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia", Blood, 127, pp.2391~2405 (2016)
8. Titmarsh GJ, "How common are myeloproliferative neoplasms? A systematic review and meta-analysis", Am J Hematol, 89, pp.581~587 (2014)
9. Mehta J, "Epidemiology of myeloproliferative neoplasms in the United States", Leuk Lymphoma, 55, pp.595~600 (2014)
10. Roaldsnes C, "Myeloproliferative neoplasms : trends in incidence, prevalence and survival in Norway", Eur J Haematol, 98, pp.85~93 (2017)
11. Hong J, "Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms", Blood Adv, 3, pp.3700~3708 (2019)
12. Brunner AM, "A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database", Leuk Lymphoma, 57, pp.1197~1200 (2016)
13. Landtblom AR, "Second malignancies in patients with myeloproliferative neoplasms : a population-based cohort study of 9379patients", Leukemia, 32, pp.2203~2210 (2018)
14. Tefferi A, "The 2008 World Health Organization classification system for myeloproliferative neoplasms : order out of chaos", Cancer, 115, pp.3842~3847 (2009)
15. Barbui T, "Masked polycythemia vera(mPV) : results of an international study", Am J Hematol, 89, pp.52~54 (2014)
16. Scott LM, "JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis", N Engl J Med, 356, pp.459~468 (2007)
17. Pietra D, "Somatic mutations of JAK2 exon 12 in patients with JAK2(V617F)-negative myeloproliferative disorders", Blood, 111, pp.1686~1689 (2008)
18. Passamonti F, "Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations", Blood, 117, pp.2813~2816 (2011)
19. Senin A, "Nondriver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up", Ann Hematol, 97, pp.443~451 (2018)
20. Crisa E, "A retrospective study on 226 polycythemia vera patients : impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and nonalkylating drugs", Ann Hematol, 89, pp.691~699 (2010)
21. Passamonti F, "A prospective study of 338 patients with polycythemia vera : the impact of JAK2(V617F)allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications", Leukemia, 24, pp.1574~1579 (2010)
22. Marchioli R, "Vascular and neoplastic risk in a large cohort of patients with polycythemia vera", J Clin Oncol, 23, pp.2224~2232 (2005)
23. Cervantes F, "Life expectancy and prognostic factors in the classic BCR", ABL-negative myeloproliferative disorders, 2008, pp.22, 905~914
24. Barbui T, "Front-line therapy in polycythemia vera and essential thrombocythemia", Blood Rev, 26, pp.205~211 (2012)
25. Barbui T, "Philadelphia chromosome-negative classical myeloproliferative neoplasms : revised management recommendations from European LeukemiaNet", Leukemia, 32, pp.1057~1069 (2018)
26. Pearson TC, "Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia", Lancet, 2, pp.1219~1222 (1978)
27. Marchioli R, "Cardiovascular events and intensity of treatment in polycythemia vera", N Engl J Med, 368, pp.22~33 (2013)
28. Landolfi R, "Efficacy and safety of low-dose aspirin in polycythemia vera", N Engl J Med, 350, pp.114~124 (2004)
29. Barbui T, "Philadelphianegative classical myeloproliferative neoplasms : critical concepts and management recommendations from European LeukemiaNet", J Clin Oncol, 29, pp.761~770 (2011)
30. Barosi G, "Revised response criteria for polycythemia vera and essential thrombocythemia : an ELN and IWG-MRT consensus project", Blood, 121, pp.4778~4781 (2013)
31. Carobbio A, "Hydroxyurea in essential thrombocythemia : rate and clinical relevance of responses by European LeukemiaNet criteria", Blood, 116, pp.1051~1055 (2010)
32. Alvarez-Larran A, "Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera", Blood, 119, pp.1363~1369 (2012)
33. Landolfi R, "Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera", Blood, 109, pp.2446~2452 (2007)
34. Barbui T, "White blood cell counts and thrombosis in polycythemia vera : a subanalysis of the CYTO-PV study", Blood, 126, pp.560~561 (2015)
35. Vannucchi AM, "Ruxolitinib versus standard therapy for the treatment of polycythemia vera", N Engl J Med, 372, pp.426~435 (2015)
36. Kiladjian JJ, "Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera(RESPONSE) : 5-year follow up of a phase 3 study", Lancet Haematol, 7, pp.e226~e237 (2020)
37. Yacoub A, "Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea", Blood, 134, pp.1498~1509 (2019)
38. Silver RT, "Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha", Cancer, 107, pp.451~458 (2006)
39. Passamonti F, "Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly(RESPONSE-2) : a randomised, open-label, phase 3b study", Lancet Oncol, 18, pp.88~99 (2017)
40. Kralovics R, "A gainof-function mutation of JAK2 in myeloproliferative disorders", N Engl J Med, 352, pp.1779~1790 (2005)
41. Levine RL, "Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis", Cancer Cell, 7, pp.387~397 (2005)
42. Klampfl T, "Somatic mutations of calreticulin in myeloproliferative neoplasms", N Engl J Med, 369, pp.2379~2390 (2013)
43. Nangalia J, "Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2", N Engl J Med, 369, pp.2391~2405 (2013)
44. Pardanani AD, "MPL515 mutations in myeloproliferative and other myeloid disorders : a study of 1182 patients", Blood, 108, pp.3472~3476 (2006)
45. Pikman Y, "MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia", PLoS Med, 3, pp.e270~ (2006)
46. Beer PA, "MPL mutations in myeloproliferative disorders : analysis of the PT-1 cohort", Blood, 112, pp.141~149 (2008)
47. Rotunno G, "Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia", Blood, 123, pp.1552~1555 (2014)
48. Rumi E, "JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes", Blood, 123, pp.1544~1551 (2014)
49. Elala YC, "Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia", Am J Hematol, 91, pp.503~506 (2016)
50. Finazzi G, "Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia", Blood, 124, pp.2611~2612 (2014)
51. Tefferi A, "Targeted deep sequencing in polycythemia vera and essential thrombocythemia", Blood Adv, 1, pp.21~30 (2016)
52. Barbui T, "Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia(IPSET-thrombosis)", Blood, 120, pp.5128~5133 (2012)
53. Barbui T, "Practicerelevant revision of IPSET-thrombosis based on 1019patients with WHO-defined essential thrombocythemia", Blood Cancer J, 5, pp.e369~ (2015)
54. Bose P, "Updates in the management of polycythemia vera and essential thrombocythemia", Ther Adv Hematol, 10, pp.2040620719870052~ (2019)
55. Ruggeri M, "No treatment for low-risk thrombocythaemia : results from a prospective study", Br J Haematol, 103, pp.772~777 (1998)
56. Tefferi A, "Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?", Blood, 108, pp.2493~2494 (2006)
57. Fenaux P, "Clinical course of essential thrombocythemia in 147 cases", Cancer, 66, pp.549~556 (1990)
58. Bellucci S, "Essential thrombocythemias. Clinical evolutionary and biological data", Cancer, 58, pp.2440~2447 (1986)
59. Budde U, "Acquired von Willebrand’s disease in the myeloproliferative syndrome", Blood, 64, pp.981~985 (1984)
60. Harrison CN, "Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia", N Engl J Med, 353, pp.33~45 (2005)
61. Samuelson B, "Anagrelide compared with hydroxyurea in essential thrombocythemia : a meta-analysis", J Thromb Thrombolysis, 40, pp.474~479 (2015)
62. Gisslinger H, "Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia : the ANAHYDRET Study, a randomized controlled trial", Blood, 121, pp.1720~1728 (2013)
63. Hernandez-Boluda JC, "Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance", intolerance to hydroxycarbamide in essential thrombocythaemia, 2011, pp.152, 81~88
64. Quintas-Cardama A, "Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a", Blood, 122, pp.893~901 (2013)
65. Masarova L, "Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera : a post-hoc, median 83 month follow-up of an open-label, phase 2 trial", Lancet Haematol, 4, pp.e165~e175 (2017)
66. Langer C, "Pegylated interferon for the treatment of high risk essential thrombocythemia : results of a phase II study", Haematologica, 90, pp.1333~1338 (2005)
67. Harrison CN, "Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide", Blood, 130, pp.1889~1897 (2017)
68. Passamonti F, "Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2(617V>F)mutation", Blood, 110, pp.485~489 (2007)
69. Alimam S, "Pregnancy outcomes in myeloproliferative neoplasms : UK prospective cohort study", Br J Haematol, 175, pp.31~36 (2016)
70. Griesshammer M, "Essential thrombocythemia and pregnancy", Leuk Lymphoma, 22(Suppl 1), pp.57~63 (1996)
71. Martinelli P, "Interferon alfa treatment for pregnant women affected by essential thrombocythemia : case reports and a review", Am J Obstet Gynecol, 191, pp.2016~2020 (2004)
72. Delage R, "Treatment of essential thrombocythemia during pregnancy with interferon-alpha", Obstet Gynecol, 87(5 Pt 2), pp.814~817 (1996)
73. Milano V, "Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-alpha 2a", J Matern Fetal Med, 5, pp.74~78 (1996)
74. Maze D, "Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes : a systematic review and meta-analysis", JAMA Netw Open, 2, pp.e1912666~ (2019)
75. Skeith L, "Risk of venous thromboembolism in pregnant women with essential thrombocythemia : a systematic review and meta-analysis", Blood, 129, pp.934~939 (2017)
76. Barbui T, "Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis : an international study", J Clin Oncol, 29, pp.3179~3184 (2011)
77. Mudireddy M, "Prefibrotic versus overtly fibrotic primary myelofibrosis : clinical, cytogenetic, molecular and prognostic comparisons", Br J Haematol, 182, pp.594~597 (2018)
78. Guglielmelli P, "Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients", Am J Hematol, 91, pp.918~922 (2016)
79. Guglielmelli P, "Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis", Blood, 129, pp.3227~3236 (2017)
80. Mesa RA, "The burden of fatigue and quality of life in myeloproliferative disorders(MPDs) : an international Internet-based survey of 1179MPD patients", Cancer, 109, pp.68~76 (2007)
81. Scherber RM, "Symptom burden as primary driver for therapy in patients with myelofibrosis : an analysis by MPN international quality of life study group", Blood, 128, pp.3117~ (2016)
82. Mesa RA, "The Myelofibrosis Symptom Assessment Form(MFSAF) : an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis", Leuk Res, 33, pp.1199~1203 (2009)
83. Emanuel RM, "Myeloproliferative neoplasm(MPN)symptom assessment form total symptom score : prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs", J Clin Oncol, 30, pp.4098~4103 (2012)
84. Tefferi A, "Type 1 vs type 2 calreticulin mutations in primary myelofibrosis : differences in phenotype and prognostic impact", Leukemia, 28, pp.1568~1570 (2014)
85. Spivak JL, "Myeloproliferative neoplasms", N Engl J Med, 376, pp.2168~2181 (2017)
86. Tefferi A, "CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis : clinical, cytogenetic and molecular comparisons", Leukemia, 28, pp.1472~1477 (2014)
87. Vannucchi AM, "Mutations and prognosis in primary myelofibrosis", Leukemia, 27, pp.1861~1869 (2013)
88. Cervantes F, "New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment", Blood, 113, pp.2895~2901 (2009)
89. Passamonti F, "Dynamic International Prognostic Scoring System(DIPSS)predicts progression to acute myeloid leukemia in primary myelofibrosis", Blood, 116, pp.2857~2858 (2010)
90. Gangat N, "DIPSS plus : a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status", J Clin Oncol, 29, pp.392~397 (2011)
91. Guglielmelli P, "The number of prognostically detrimental mutations and prognosis in primary myelofibrosis : an international study of 797patients", Leukemia, 28, pp.1804~1810 (2014)
92. Guglielmelli P, "MIPSS70 : mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis", J Clin Oncol, 36, pp.310~318 (2018)
93. Tefferi A, "MIPSS70+ version 2. 0 : mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis", J Clin Oncol, 36, pp.1769~1770 (2018)
94. Tefferi A, "GIPSS : genetically inspired prognostic scoring system for primary myelofibrosis", Leukemia, 32, pp.1631~1642 (2018)
95. Tefferi A, "Primary myelofibrosis : 2019 update on diagnosis, risk-stratification and management", Am J Hematol, 93, pp.1551~1560 (2018)
96. Odenike O, "Conventional and new treatment options for myelofibrosis with myeloid metaplasia", Semin Oncol, 32, pp.422~431 (2005)
97. Martinez-Trillos A, "Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis : results in 40 patients", Ann Hematol, 89, pp.1233~1237 (2010)
98. Abelsson J, "The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries", Bone Marrow Transplant, 47, pp.380~386 (2012)
99. Mesa RA, "The evolving treatment paradigm in myelofibrosis", Leuk Lymphoma, 54, pp.242~251 (2013)
100. Verstovsek S, "A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis", N Engl J Med, 366, pp.799~807 (2012)
101. Harrison C, "JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis", N Engl J Med, 366, pp.787~798 (2012)
102. Cervantes F, "Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis", Blood, 122, pp.4047~4053 (2013)
103. Pardanani A, "Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis : a randomized clinical trial", JAMA Oncol, 1, pp.643~651 (2015)
104. Harrison CN, "Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib(JAKARTA-2) : a singlearm, open-label, non-randomised, phase 2, multicentre study", Lancet Haematol, 4, pp.e317~e324 (2017)
105. Mascarenhas J, "Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis : a randomized clinical trial", JAMA Oncol, 4, pp.652~659 (2018)
106. Harrison CN, "Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib(SIMPLIFY 2) : a randomised, open-label, phase 3 trial", Lancet Haematol, 5, pp.e73~e81 (2018)
107. Cervantes F, "How I treat myelofibrosis", Blood, 124, pp.2635~2642 (2014)
108. Deininger M, "The effect of long-term ruxolitinib treatment on JAK2p. V617F allele burden in patients with myelofibrosis", Blood, 126, pp.1551~1554 (2015)
109. Ianotto JC, "Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis : a French Intergroup of Myeloproliferative neoplasms(FIM)study", Haematologica, 103, pp.438~446 (2018)
110. Sorensen AL, "Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis : a phase II study", Haematologica, 105, pp.235648~ (2019)
111. Tefferi A, "Revised response criteria for myelofibrosis : International Working GroupMyeloproliferative Neoplasms Research and Treatment(IWG-MRT)and European LeukemiaNet(ELN)consensus report", Blood, 122, pp.1395~1398 (2013)
112. Huang J, "Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level", Eur J Haematol, 83, pp.154~155 (2009)
113. Cervantes F, "Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia : results in 20 patients and review of the literature", Br J Haematol, 127, pp.399~403 (2004)
114. Cervantes F, "Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia", Br J Haematol, 134, pp.184~186 (2006)
115. Cervantes F, "Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia : long-term results in 30 patients", Br J Haematol, 129, pp.771~775 (2005)
116. Cervantes F, "Danazol therapy for the anemia of myelofibrosis : assessment of efficacy with current criteria of response and long-term results", Ann Hematol, 94, pp.1791~1796 (2015)
117. Mesa RA, "A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia", Blood, 101, pp.2534~2541 (2003)
118. Mesa RA, "Lenalidomide and prednisone for myelofibrosis : Eastern Cooperative Oncology Group(ECOG)phase 2 trial E4903", Blood, 116, pp.4436~4438 (2010)
119. Ballen KK, "Outcome of transplantation for myelofibrosis", Biol Blood Marrow Transplant, 16, pp.358~367 (2010)
120. Passamonti F, "A dynamic prognostic model to predict survival in primary myelofibrosis : a study by the IWG-MRT(International Working Group for Myeloproliferative Neoplasms Research and Treatment)", Blood, 115, pp.1703~1708 (2010)
121. Kroger N, "Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis", Blood, 125, pp.3347~3350 (2015)
122. Gupta V, "Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors", Blood, 120, pp.1367~1379 (2012)
123. McLornan DP, "Allogeneic stem cell transplantation for myelofibrosis in 2012", Br J Haematol, 157, pp.413~425 (2012)
124. Reilly JT, "Guideline for the diagnosis and management of myelofibrosis", Br J Haematol, 158, pp.453~471 (2012)
125. Tefferi A, "Primary myelofibrosis : 2013 update on diagnosis, risk-stratification, and management", Am J Hematol, 88, pp.141~150 (2013)
126. Gagelmann N, "Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation", Blood, 133, pp.2233~2242 (2019)
127. Shanavas M, "Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1", 2inhibitors, 2016, pp.22, 432~440
128. Hanif A, "Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms", Bone Marrow Transplant, 51, pp.617~618 (2016)
129. Salit RB, "Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis", Bone Marrow Transplant, 55, pp.70~76 (2020)

관련 논문AI추천